Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Global change in chest pain at the 12 weeks
研究概览
简要总结
The primary aim is to develop and test the feasibility of a standardized digital audio home-hypnotherapy (HHT) program for patients with refractory functional chest pain (FCP).
The secondary aims of this study are:
- To obtain pilot data to assess the magnitude of the treatment effect of self-hypnosis in refractory FCP for an anticipated future, larger treatment trial;
- To determine the stability of the treatment effect of HHT in refractory FCP;
- To assess the relationship between response to HHT and psychological factors; and
- To assess the relationship between response to HHT and symptomatic dimensions of chest pain (severity, frequency, and duration).
- To assess the difference
详细描述
Eligible patients with refractory FCP will be randomized to one of 2 arms: the active treatment group, who will receive the HHT program; or a control group. Patients in the active treatment group will receive the 12-week digital audio HHT program. This protocol consists of 7 sessions, each approximately 30-40 minutes, administered every 2 weeks, for a cumulative 12 weeks of treatment, along with a shorter (approximately 12 minute) session administered daily. Patients in the control group will receive a digital audio educational program. Subjects in both groups will be assessed at baseline, 4-6 weeks into treatment, at the end of the treatment, and 3 months after conclusion of the program. Global change in symptoms will be assessed with a 7-point Likert scale. Patients will be considered to respond if they have significant improvement on the Likert scale at the post-treatment visit. Patients will complete a chest pain symptom diary, the SCL-90 and the Coping Strategies Questionnaire-Catastrophizing subscale to assess psychological features, and the SF-36 as a measure of Health Related Quality of Life (HRQOL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 80, male or female.
- •Patients must fulfill the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin for the previous 3 months (with symptom onset at least 6 months before diagnosis), including all of the following:
- •Midline chest pain or discomfort that is not of burning quality
- •Absence of evidence that gastroesophageal reflux is the cause of the symptom
- •Absence of histopathology-based esophageal motility disorders
- •Persistent symptoms despite a trial of antidepressant therapy, as defined by either:
- •chest pain despite at least a continuous 4-week trial of at least one antidepressant within the last 6 months; or
- •intolerance of at least one antidepressant within the last 6 months.
- •Negative cardiac evaluation (negative cardiac stress test or negative coronary angiogram)
- •Negative gastrointestinal evaluation for cause of the pain, defined by absence of Los Angeles grade C or D erosive esophagitis on endoscopy, persistent chest pain on PPI therapy, and no association of chest pain with reflux episodes on an ambulatory pH or pH-impedance study, defined as a symptom index <50% or symptom association probability <95% for chest pain .
排除标准
- •Severe co-morbid illness (cardiac, pulmonary, renal, hematologic, hepatic)
- •Prior treatment with hypnosis/hypnotherapy for a medical condition
- •Prior major thoracic surgery
- •Prior diagnosis of or treatment for dissociative disorders, post-traumatic stress disorder, borderline personality disorder, or other psychiatric disorders that include psychotic features
- •Pregnancy or planned pregnancy within the upcoming 3 months
- •Inability or unwillingness to give informed consent
研究组 & 干预措施
Hypnotherapy
Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
干预措施: Home Hypnotherapy (Behavioral)
Educational
Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
干预措施: Educational (Behavioral)
结局指标
主要结局
Global change in chest pain at the 12 weeks
时间窗: 12 Weeks Post Treatment Start
To fulfill Rome III recommendations for the design of treatment trials for Functional Gastrointestinal Disorders (FGIDS),47 we will use a 7-point Likert scale to assess for global change in chest pain. At times V2, V3, and V4, patients will be asked the following question: "Compared to before starting this therapy, how would you rate your chest pain?" The following answers will be given as options: "much better" (+3), "somewhat better" (+2), "minimally better" (+1), "no change" (0), "minimally worse" (-1), "somewhat worse" (-2), "much worse" (-3).
次要结局
- Global change in chest pain at 4 weeks(4 Weeks Post Treatment Start)
- Global change in chest pain at 6 weeks(6 Weeks Post Treatment Start)
- Change in symptom score at 3 months(12 Weeks Post Treatment Start)
- Change in psychometric score at 3 months(12 Weeks Post Treatment Start)
- Change in HRQOL scores at 3 months(12 Weeks Post Treatment Start)
研究者
Ryan Madanick, MD
Assistant Professor of Medicine Director, UNC Gastroenterology & Hepatology Fellowship Program
University of North Carolina, Chapel Hill